Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors

By LabMedica International staff writers
Posted on 09 May 2025

Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. More...

Introducing a flexible, decentralized sequencing system at the point of care, which requires minimal technical oversight, could significantly improve turnaround times and expand patient access to genomic profiling. In a new study, researchers assessed the clinical feasibility of an automated, decentralized cfDNA next-generation sequencing (NGS) assay designed to identify actionable genetic alterations in advanced solid tumors.

The study, conducted by researchers at the Japanese Foundation for Cancer Research (JFCR, Tokyo, Japan), involved genomic profiling of plasma cfDNA from 298 patients with advanced solid tumors using an automated NGS assay. The team compared the tumor mutations detected in plasma cfDNA with those found in patient-matched tumor tissues, which were analyzed using an FDA-approved assay. They also examined clinical factors that could influence the sensitivity of ctDNA aberration (mut-ctDNA) detection. The researchers discovered that the sequencing success rates for cfDNA genomic profiling were significantly higher compared to archived tumor tissue (99% vs. 96%). The detection rates of mut-ctDNA ranged from 20% to 67% across various solid tumors, and targetable or resistance alterations were identified in 18% of patients.

The results, published in the journal Clinical Chemistry, also revealed that approximately 72% of patients showed consistent alterations between tissue and plasma samples. This level of concordance was linked to factors such as cancer type, tumor burden, and the metastatic location. Importantly, 63 plasma-only alterations were identified in 18% of patients, with these alterations being more common in patients who had previously received targeted treatments (24%) compared to those who had undergone chemotherapy (10%). The findings highlight the clinical viability of an automated, decentralized cfDNA genomic profiling method and emphasize the need to consider clinical factors when choosing between plasma- or tissue-based assays. This approach holds promise for improving patient access to timely genomic profiling and facilitating targeted therapy selection.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.